Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Autoimmune Archive
2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020 - 2019 - 2018 - 2017

August 2017 Autoimmune News

The effect of cryotherapy on total antioxidative capacity in patients with active seropositive rheumatoid arthritis. The effect of cold treatments was examined on the antioxidative capacity of rheumatoid arthritis (RA) patients with active disease. PubMed, Rheumatol Int, 07/11/2017. (Also see Treatments for Rheumatoid Arthritis)

Medial prefrontal cortex deficits correlate with unrefreshing sleep in patients with chronic fatigue syndrome (CFS). This study is the first to report that brain structural differences are associated with unrefreshing sleep in CFS and this result refutes the suggestion that unrefreshing sleep is a misperception in CFS patients and further investigation of this symptom is warranted. PubMed, NMR Biomed, 06/29/2017. (Also see Chronic Fatigue Syndrome)

Circulating osteoprotegerin levels are elevated in rheumatoid arthritis (RA): a systematic review and meta–analysis. Our meta–analysis revealed a significantly higher circulating osteoprotegerin level in RA patients, and it was influenced by race, disease duration, body mass index and disease activity score based on the assessment of 28 joints. PubMed, Clin Rheumatol, 07/11/2017. (Also see Diagnosis of Rheumatoid Arthritis)

A retrospective study of joint infections in patients with systemic lupus erythematosus (SLE). When an SLE patient presents with pre–existing arthritis and suddenly develops asymmetric oligo– or large–joint swelling and pain with elevated C-reactive protein levels and low disease activity, joint infections should be considered. PubMed, Clin Rheumatol, 07/08/2017. (Also see Symptoms and Complications of Lupus)

Hyperuricemia is an independent risk factor for psoriatic arthritis (PsA) in psoriatic patients. Hyperuricemia may increase uric acid crystallization in and around joints, thereby inducing PsA in psoriatic subjects and it appears to be an independent risk factor for PsA. PubMed, J Dermatol, 07/10/2017. (Also see Psoriasis and Psoriatic Arthritis)

Interleukin-20 is triggered by toll–like receptor ligands (TLR) and associates with disease activity in patients with rheumatoid arthritis (RA). Our data showed that IL-20 is independently associated with RA disease activity and may be triggered by TLR ligands at local sites of inflammation. PubMed, Cytokine, 2017 Sep;97:187-192. (Also see Causes of Rheumatoid Arthritis and Interleukins)

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Treatment with anti–CD20 agents can be guided by B-cell monitoring and should aim to achieve complete depletion. PubMed, Ann Rheum Dis, 07/06/2017. (Also see Treatments for Lupus and B Cells and T Cells)

Low concentrations of bisphenol A (BPA) promote human ovarian cancer cell proliferation and glycolysis–based metabolism through the estrogen receptor (ER)– α pathway. Our findings revealed a new mechanism through which BPA promoted cell proliferation by reinforcing glycolysis–based energy production dependent on ER signaling. PubMed, Chemosphere, 2017 Jul 9;185:361-367. (Also see Cancer)

State of the art on nailfold capillaroscopy (NFC) in dermatomyositis (DM) and polymyositis (PM). The overview confirms that NFC is a safe and noninvasive tool able to help the clinician in the diagnosis of DM and PM and to better characterize the phase of disease activity of these patients. PubMed, Semin Arthritis Rheum, 06/28/2017. (Also see Dermatomyositis and Polymyositis and Nailfold Capillaroscopy)

Case Report: NXP-2 Positive Dermatomyositis: A Unique Clinical Presentation. Nuclear matrix protein (NXP-2) antibodies have been described as a myositis–specific antibody that may aid in the diagnostic evaluation. PubMed, Case Rep Rheumatol, 2017;2017:4817275. (Also see Dermatomyositis and Polymyositis)

Go to Autoimmune News: July 2017

We have the world's best supporters! See ISN News.


SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.

The most important thing in the world to know about scleroderma is!